Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy

[1]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[4]  B. Mounho,et al.  Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics , 2005, International journal of toxicology.

[5]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[6]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[7]  E. Ward,et al.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.

[8]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[9]  S. Guichard,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1998.0364 CPT-11 converting carboxylesterase and topoisomerase I , 2022 .

[10]  A. Kurita,et al.  High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[11]  L. Wienkers,et al.  Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[12]  J. Armand,et al.  Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  S. Wadler,et al.  A REVIEW OF THE CLINICAL EXPERIENCE WITH IRINOTECAN (CPT‐11) , 1997, American journal of therapeutics.